Investor Presentaiton

Acronyms 6MWT Six Minute Walk Test HDT High Dose Therapy NTRK AA Alopecia Areata HFPEF Heart Failure with Preserved Ejection Fraction NYHA ACR American College of Rheumatology HFrEF Heart Failure with Reduced Ejection Fraction OHCM ACS Acute Coronary Syndrome IBD Inflammatory Bowel Disease ORR ADC Antibody-Drug Conjugate ICANS Immune Effector Cell-associated Neurotoxicity Syndrome OS ADT Androgen Deprivation Therapy iiNT Investigator-identified Neurotoxicity PFS AF Atrial Fibrillation ILD Interstitial Lung Disease PI Al Artificial Intelligence IMID Immunomodulary Drug PoC ALS Amyotrophic Lateral Sclerosis IND Investigational New Drug POS AML Acute Myeloid Leukemia 10 Immuno-Oncology PPF Neurotrophic Tyrosine Receptor Kinase New York Heart Association Obstructive Hypertrophic Cardiomyopathy Overall Response Rate Overall Survival Progression-free Survival Proteosome Inhibitor Proof of Concept Probability of Success Progressive Pulmonary Fibrosis APC Antigen-Presenting Cell IPF AR LDD Androgen Receptor Ligand-Directed Degrader IPI ASCT Autologous Stem Cell Transplant IRA Idiopathic Pulmonary Fibrosis Inflation Reduction Act PPFVC Percent of Predicted Forced Vital Capacity International Prognostic Index PR Partial Response PsA Psoriatic Arthritis BCMA B-cell Maturation Antigen ISR Integrated Stress Response PSA Prostate Specific Antigen BID Twice Daily JAK2i Janus Kinase 2 Inhibitor PsO Psoriasis BILAG BL British Isles lupus Assessment Group index Baseline LBCL Large B-cell Lymphoma PTCL Peripheral T-cell Lymphoma LDD Ligand-directed Degrader QD Once Daily CAR T Chimeric Antigen Receptor T-cell LOE Loss of Exclusivity QoL CD Crohn's Disease LPA1 Lysophosphatidic Acid Receptor 1 R CELMOD Cereblon E3 Ligase Modulator MAB Monoclonal Antibody RA Quality of Life Randomized Rheumatoid Arthritis CLASI Cutaneous Lupus Activity Index MCL Mantle Cell Lymphoma RBC Red Blood Cell CLL Chronic Lymphocytic Leukemia mCRPC Metastatic Castration-resistant Prostate Cancer RCC Renal Cell Carcinoma CPI Checkpoint Inhibitor MDOR Median Duration of Response ROS C-ros Oncogene CRPC Castration-Resistant Prostate Cancer MDS Myelodysplastic Syndrome RWE Real-World Evidence CRS Cytokine Release Syndrome MF Myelofibrosis SC Subcutaneous CV Cardiovascular MIUC Muscle-invasive Urothelial Carcinoma SCR DIPSS Dynamic International Prognostic Scoring System ML Machine Learning SjS Stringent Complete Response Sjogren's Syndrome DLT DMPK EGE Dose-Limiting Toxicity Eosinophilic Gastroenteritis MM Multiple Myeloma SLE Systemic Lupus Erythematosus Drug Metabolism Pharmacokinetics МоА Mechanism of Action SLEDAI-2K SLE Disease Activity Index 2000 mPC Metastatic Prostate Cancer SLL EoE Eosinophilic Esophagitis MPN Myeloproliferative Neoplasm SoC Standard of Care ESSDAI EULAR Sjögren's Syndrome Disease Activity Index MRD Minimal Residual Disease SRI(4) ESSPRI EULAR EULAR Sjögren's Syndrome Patient Reported Index European League Against Rheumatism MS Multiple Sclerosis SSP MSS MCRC Microsatellite Stable Metastatic Colorectal Cancer TA FL Follicular Lymphoma MZL Marginal Zone Lymphoma TCE Flu/Cy Fludarabine and Cyclophosphamide NDMM Newly Diagnosed Multiple Myeloma TD FVC Forced Vital Capacity NFPB Non-fucosylated Probody TIGIT FXa Factor 10a nHCM Non-obstructive Hypertrophic Cardiomyopathy TKI FXla Factor 11a NHL Non-hodgkin's Lymphoma TKR GI Gastrointestinal NHT GPRC5D HbF G Protein Coupled Receptor, Class C, Group 5, Member D Fetal Hemoglobin NSCLC NT HCC Hepatocellular Carcinoma NTD Novel Hormone Therapy Neurotoxicity Non-transfusion Dependent TRAE Small Lymphocytic Lymphoma Systemic Lupus Erythematosus Responder Index 4 Secondary Stroke Prevention Therapeutic Area T-cell Engager Transfusion Dependent T-cell Immunoglobulin and ITIM Domain Tyrosine Kinase Inhibitor Total Knee Replacement Treatment-related Adverse Event Non-small Cell Lung Cancer TYK2 Tyrosine Kinase 2 UC Ulcerative Colitis VGPR Very Good Partial Response Ill Bristol Myers Squibb™ Not for Product Promotional Use 145

View entire presentation